Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11239-020-02212-6 http://scihub22266oqcxt.onion/10.1007/s11239-020-02212-6 32632558!7338133!32632558     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Thrombolysis 2021 ; 51 (1): 226-231 Nephropedia Template TP {{tp|p=32632558|t=2021. Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?|pdf=|usr=}}{{32632558}} gab.com Text Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory JO: J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=32632558 #FOAvip Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been linked to a higher risk of mortality compared to influenza, which is mainly due to severe secondary diseases, such as acute respiratory distress syndrome (ARDS). In turn, ARDS is characterized by an acute inflammation and an excessive activity of the coagulation cascade, rising the vulnerability for venous thromboembolic events. In order to investigate the relation of inflammation and the influence of coagulation factors on their release, human peripheral mononuclear blood cells (PBMCs) were treated with autologous serum, heparinized plasma and different doses of fibrin. Thereafter, the concentration of pro-inflammatory cytokines and chemokines in the secretome of PBMCs was measured by enzyme-linked immunosorbent assay. Our analyses revealed autologous serum to significantly increase the secretion of cytokines and chemokines after 24 h of incubation time. Furthermore, the addition of fibrin markedly increased the secretion of cytokines and chemokines by PBMCs in a dose-dependent manner. Consequently, in accordance with previous studies, our study outlines that anti-coagulation may constitute a promising tool for the treatment of SARS-CoV-2, reducing both, the cytokine storm, as well as the risk for thrombotic complications. Twit Text FOAVip Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory ????J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=32632558 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32632558 #FOAvip English Wikipedia <ref>{{Cite pmid|32632558}}</ref> Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory? #MMPMID32632558 Paar V; Wernly B; Zhou Z; Motloch LJ; Hoppe UC; Egle A; Lichtenauer M J Thromb Thrombolysis 2021[Jan]; 51 (1): 226-231 PMID32632558show ga Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been linked to a higher risk of mortality compared to influenza, which is mainly due to severe secondary diseases, such as acute respiratory distress syndrome (ARDS). In turn, ARDS is characterized by an acute inflammation and an excessive activity of the coagulation cascade, rising the vulnerability for venous thromboembolic events. In order to investigate the relation of inflammation and the influence of coagulation factors on their release, human peripheral mononuclear blood cells (PBMCs) were treated with autologous serum, heparinized plasma and different doses of fibrin. Thereafter, the concentration of pro-inflammatory cytokines and chemokines in the secretome of PBMCs was measured by enzyme-linked immunosorbent assay. Our analyses revealed autologous serum to significantly increase the secretion of cytokines and chemokines after 24 h of incubation time. Furthermore, the addition of fibrin markedly increased the secretion of cytokines and chemokines by PBMCs in a dose-dependent manner. Consequently, in accordance with previous studies, our study outlines that anti-coagulation may constitute a promising tool for the treatment of SARS-CoV-2, reducing both, the cytokine storm, as well as the risk for thrombotic complications. |*Blood Coagulation/drug effects/immunology[MESH] |*Cytokine Release Syndrome/blood/drug therapy/etiology[MESH] |*Fibrin/immunology/pharmacology[MESH] |*Inflammation/blood/therapy[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/blood/immunology/*therapy[MESH] |Cells, Cultured[MESH] |Chemokines/immunology[MESH] |Dose-Response Relationship, Drug[MESH] |Fibrinolytic Agents/pharmacology[MESH] |Heparin/pharmacology[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Leukocytes, Mononuclear/drug effects[MESH]Anti-coagulation for COVID-19 treatment: both anti-thrombotic and ant(epmc).pdf DeepDyve Pubget Overpricing